Literature DB >> 23052344

[In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].

T Gaiser1, J Rüschoff, R Moll.   

Abstract

The introduction of total genome sequencing led to the confirmation that tumors show substantial genetic heterogeneity. This phenomenon, which describes the presence of different genetic cell clones within a tumor also complicates the diagnostics of HER2. This article gives a review of new knowledge on polysomy 17 and genetic tumor heterogeneity in connection with HER2 determination of breast cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23052344     DOI： 10.1007/s00292-012-1663-z

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  12 in total

1.  Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.

Authors:  Sudha S Murthy; D G Sandhya; Faiq Ahmed; K Iravathy Goud; Monal Dayal; K Suseela; Senthil J Rajappa
Journal:  Indian J Pathol Microbiol       Date:  2011 Jul-Sep       Impact factor: 0.740

2.  Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.

Authors:  Raymond R Tubbs; David G Hicks; James Cook; Erinn Downs-Kelly; James Pettay; Mary Beth Hartke; Lashonda Hood; Rosemary Neelon; Jonathan Myles; George Thomas Budd; Halle C Moore; Steve Andresen; Joseph P Crowe
Journal:  Diagn Mol Pathol       Date:  2007-12

Review 3.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Authors:  Therese B Bevers; Benjamin O Anderson; Ermelinda Bonaccio; Saundra Buys; Sandra Buys; Mary B Daly; Peter J Dempsey; William B Farrar; Irving Fleming; Judy E Garber; Randall E Harris; Alexandra S Heerdt; Mark Helvie; John G Huff; Nazanin Khakpour; Seema A Khan; Helen Krontiras; Gary Lyman; Elizabeth Rafferty; Sara Shaw; Mary Lou Smith; Theodore N Tsangaris; Cheryl Williams; Thomas Yankeelov; Thomas Yaneeklov
Journal:  J Natl Compr Canc Netw       Date:  2009-11       Impact factor: 11.908

4.  Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

Authors:  Alastair I Bartlett; Jane Starcyznski; Tammy Robson; Alex Maclellan; Fiona M Campbell; Cornelis J H van de Velde; Annette Hasenburg; Christos Markopoulos; Caroline Seynaeve; Daniel Rea; John M S Bartlett
Journal:  Am J Clin Pathol       Date:  2011-08       Impact factor: 2.493

5.  Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

Authors:  Chun Hing Tse; Harry C Hwang; Lynn C Goldstein; Patricia L Kandalaft; Jesse C Wiley; Steven J Kussick; Allen M Gown
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

6.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  Genome and transcriptome profiles of CD133-positive colorectal cancer cells.

Authors:  Timo Gaiser; Jordi Camps; Sandra Meinhardt; Danny Wangsa; Quang Tri Nguyen; Sudhir Varma; Claudia Dittfeld; Leoni A Kunz-Schughart; Ralf Kemmerling; Maria R Becker; Kerstin Heselmeyer-Haddad; Thomas Ried
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

8.  Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

Authors:  Gail H Vance; Todd S Barry; Kenneth J Bloom; Patrick L Fitzgibbons; David G Hicks; Robert B Jenkins; Diane L Persons; Raymond R Tubbs; M Elizabeth H Hammond
Journal:  Arch Pathol Lab Med       Date:  2009-04       Impact factor: 5.534

9.  Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

Authors:  Isabelle Vanden Bempt; Peter Van Loo; Maria Drijkoningen; Patrick Neven; Ann Smeets; Marie-Rose Christiaens; Robert Paridaens; Christiane De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

10.  Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas.

Authors:  Timo Gaiser; Andreas Waha; Franziska Moessler; Thomas Bruckner; Torsten Pietsch; Andreas von Deimling
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842
View more
  1 in total

1.  The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas.

Authors:  Hongfei Ji; Qijia Xuan; Abiyasi Nanding; Haiyu Zhang; Qingyuan Zhang
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.